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Background: Risk-stratified management of fever with neutropenia (FN), allows intensive management of high-risk cases and early discharge of low-
risk cases. No single, internationally validated, prediction model of the risk of adverse outcomes exists for children and young people. An individual
patient data (IPD) meta-analysis was undertaken to devise one.
Methods: The ‘Predicting Infectious Complications in Children with Cancer’ (PICNICC) collaboration was formed by parent representatives,
international clinical and methodological experts. Univariable and multivariable analyses, using random effects logistic regression, were undertaken to
derive and internally validate a risk-prediction model for outcomes of episodes of FN based on clinical and laboratory data at presentation.
Results: Data came from 22 different study groups from 15 countries, of 5127 episodes of FN in 3504 patients. There were 1070 episodes in 616 patients
from seven studies available for multivariable analysis. Univariable analyses showed associations with microbiologically defined infection (MDI) in many items,
including higher temperature, lower white cell counts and acute myeloid leukaemia, but not age. Patients with osteosarcoma/Ewings sarcoma and those with
more severe mucositis were associated with a decreased risk of MDI. The predictive model included: malignancy type, temperature, clinically ‘severely
unwell’, haemoglobin, white cell count and absolute monocyte count. It showed moderate discrimination (AUROC 0.723, 95% confidence interval
0.711–0.759) and good calibration (calibration slope 0.95). The model was robust to bootstrap and cross-validation sensitivity analyses.
Conclusions: This new prediction model for risk of MDI appears accurate. It requires prospective studies assessing implementation to assist clinicians
and parents/patients in individualised decision making.
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Children developing cancer in North America and Europe have an
80% chance of cure (Pritchard-Jones et al, 2006; Ward et al, 2014).
The cost of this cure, in terms of intensity of therapy and recurrent
admissions with toxic effects, is a considerable burden upon
children, young people and their families (Chisholm and
Dommett, 2006). One such toxicity, fever with neutropenia (FN),
also known as ‘febrile neutropenia’ or ‘neutropenic sepsis’, is the
clinical dilemma of potentially severe infection in an immuno-
compromised child or a young person. Its management requires
balancing competing risks from overtreatment against under-
treatment, and personalising care in FN by accurately differentiat-
ing those at higher or lower risk of significant infection, to
determine who is eligible for alternative treatment approaches
(Lehrnbecher et al, 2012).
Current practice in managing febrile neutropenia in paediatric
oncology is variable (Chamberlain et al, 2005; Boragina and Patel,
2007; Stabell et al, 2007; Phillips et al, 2007). Some centres use a
risk-stratified reduced intensity approach directed by clinical
decision rules, whereas others treat all children with aggressive,
in-patient delivered antibiotic therapy.
Systematic reviews (Haeusler et al, 2013a, b; Phillips et al, 2010,
2012a, c) show that many clinical decision rules have been
proposed to predict which children will have poor outcomes
during episodes of febrile neutropenia. These identified several
difficulties including small numbers of patients, analysis techniques
which lead to optimistic estimates of predictive power, and
lack of validation in different geographies and care systems
(Phillips et al, 2012a).
Individual patient data (IPD) meta-analysis of data from
therapeutic studies has been developed over two decades to
improve the precision and reliability of answers to questions of
treatment, and provides a means of overcoming many such
problems (Stewart and Tierney, 2002; Riley et al, 2010). More
recently, the approach has been promoted for developing and
validating risk-prediction models from observational data, to
improve the quality of answers to important prognostic questions
(Altman and Riley, 2005) and matters of diagnostic accuracy
(Leeflang et al, 2008), and to establish more robust clinical decision
rules. Meta-analysis of IPD from multiple studies allows harmo-
nisation of study data sets, standardisation of end points and
analysis methods, as well as greater statistical power to identify
more complex statistical relationships (Stewart and Tierney, 2002).
To maximise the value of the information already collected by
previous studies and cohorts of children with febrile neutropenia, a
global collaboration (The ‘Predicting Infectious Complications in
Children with Cancer’: PICNICC) was established to facilitate an
IPD meta-analysis that aimed to robustly develop and externally
validate a new prediction model for the risk of microbiologically
defined infection (MDI) in febrile neutropenic children (Phillips
et al, 2012b).
METHODS
A detailed protocol for the PICNICC IPD study was developed,
registered and published before commencement of the analysis
(Phillips et al, 2012b). The primary aim of the IPD analysis was at
the onset of an episode of FN to quantify the risk of adverse clinical
outcomes according to clinical variables recorded in children and
young people aged 0–24 years old undergoing treatment for
malignant disease at the onset of an episode of FN, and to develop
a new risk-prediction model.
Collaboration development. The PICNICC collaboration com-
prises international clinical and methodological experts, parent
representatives and health-care researchers. Clinical and research
experts were identified from trials identified during preliminary
systematic reviews of aggregate data (Phillips et al, 2010, 2012c), in
response to oral presentations at paediatric oncology conferences,
and web-based invitations. Parents/carers were approached via UK
parent support organisations. This process led to 22 different study
groups from 15 countries joining the PICNICC collaboration.
Ethical approval for the study was granted in the UK and
individual members were advised to contact their local ethics board
to determine the need for approval (Phillips et al, 2013).
Data acquisition. Each collaborative group shared, episode-by-
episode, de-identified individual level data from their original
studies of new-onset episodes of FN as defined by the original
studies. Candidate predictors for inclusion in the risk-prediction
model were requested for each study. These were patient-level
variables measured on admission, and included: patient age at, and
date of, each episode of FN; underlying malignancy type; remission
status; chemotherapy type and date of last cycle; type of central
venous line; in/out-patient status; maximum temperature; clinical
observations including global assessment of illness severity and
mucositis; blood count parameters; inflammatory biomarkers; and
empirical antibiotics used (Phillips et al, 2012b). A minimum
requirement of patient age, malignancy type, one marker of clinical
status, antibiotics given, white cell and neutrophil counts and one
specified outcome was set. Data were mapped into similar
reporting units, for example, mmol into g dl 1, and using
predefined structures for cardiovascular, respiratory and mucositis
outcomes. The outcome used in this analysis was of MDI. We
permitted any definition described in the original study and did
not insist on the HIS consensus definition (Immunocompromised
Host Society, 1990). The majority of studies used microbiological
identification of a pathogen from a sterile site. This outcome was
chosen after data collection as it was the most frequently and
consistently reported clinically relevant outcome, and was highly
correlated with the less frequently reported ‘serious medical
complication’ as suggested by the recently published core outcome
set (Haeusler et al, 2014).
Statistical methods. IPD from the 22 data sets were cleaned, and
the availability of variables and the outcome of interest (MDI) were
summarised. Studies were excluded if they did not provide the
outcome of interest. Univariable analysis was undertaken to
examine the unadjusted effect of each candidate predictor, using
random effects logistic regression as described below. The multi-
variable risk-prediction model was developed using logistic
regression, hierarchical of episodes within studies. For multi-
variable analysis, a complete case analysis was undertaken. Studies
were removed if they had not collected information on potentially
informative variables that had been deemed important a priori and
focused on those predictors with the most complete information
(p15% missing). These were selected from variables that prior
systematic reviews suggested would provide the largest complete
data set (see Figure 1). Variables were selected for inclusion in the
model by a stepwise selection process—examining improvement in
fit with each additional variable added to the model using Akaike’s
Information Criterion (AIC), with a P-value of o0.15 and net
reclassification improvement (Pencina et al, 2008) used in
determining inclusion. Different functional forms for continuous
variables were assessed by the use of fractional polynomials before
inclusion (Royston and Sauerbrei, 2008). Clustering of patients
within studies was accounted for by fitting a random-effect on the
intercept. The impact of other potential sources of heterogeneity
(e.g., in the effects of particular variables across studies) and other
degrees of clustering (e.g., through repeated episodes of the same
individual) were evaluated with further random effects. Heuristic
shrinkage (Steyerberg, 2009) and the bootstrap procedure (Harrell
et al, 1996) using 5000 episodes with replacement were used to
adjust for potential overfitting. Performance was internally checked
using all-bar-one cross-validation predictive performance
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(Royston et al, 2004), where the model is repeatedly applied to the
derivation data after a single data set has been removed, to assess
for systematic miscalibration driven by outlying data sources. Type
of antibiotic therapy was incorporated into the model in a
sensitivity analysis, as initial discussions considered this may reflect
otherwise occult clinical suspicion of serious infection. The
calibration of the model was checked by plotting observed against
expected values for population deciles, with discrimination
calculated using the area under the receiver–operator curve
(AUROC), also known as the C-statistic.
RESULTS
Data. IPD information from 5127 episodes of FN in 3504 patients
from 22 data sets was provided for analysis (Supplementary
Table 1, online).
A wide variety of malignancies were represented in the IPD data
sets. Overall there were 52% of patients with acute leukaemias, 27%
with solid tumours of childhood, 11% with lymphoma, 7% with
brain tumours, 3% with non-malignant conditions treated with
chemotherapy (e.g., Langerhans cell histiocytosis) and 2% of
children with adult-type solid tumours (e.g., carcinomas of bowel).
Only two of the data sets (Genoa, PINE) included patients who had
undergone haemopoetic stem cell transplantation (HSCT). The
median age of the patients at first episode was 6.8 years, with a
range of 50 days to 25 years old, with 14% of patients 16 years or
older; 56% of the patients were male.
The IPD collected included a wide range of outcomes and
potential predictor variables with marked differences in complete-
ness, interpretation and consistency between data sets. No data set
completely reported every item (Figure 1). The most common
reason for absent data was that the studies did not collect that
variable. The unrecorded data effectively reduced the data set
available for multivariable analysis to around 1101 episodes in 742
patients over seven studies. The sparseness of information on
biomarkers in comparison with the clinical data meant that these
were assessed only in their univariable relationship with MDI and
not as part of a multivariable model.
We were unable to obtain data from 30 studies (including
5387 episodes) that had been identified in our previous systematic
reviews. Authors of two studies explained that they were unable to
participate because the studies were conducted over 20 years
ago and data were no longer retrievable; other study groups
did not respond or give reasons for not taking part. These
unavailable studies did not significantly differ from those included
in terms of number of participants (P¼ 0.66), number of episodes
(P¼ 0.93), number of events (P¼ 0.67) or geographical region
(P¼ 0.25).
Univariable associations with microbiologically defined
infection. The results of univariable (unadjusted) analyses showed
associations between MDI and many variables (Table 1) including
the presence of an untunnelled central line, the clinical appearance
of being significantly unwell (as defined by the original studies),
of documented cardiovascular compromise (shock), a high
temperature, raised serum biomarkers, low white cell counts,
neutrophil counts or platelets and a diagnosis of acute myeloid
leukaemia or relapsed acute leukaemia. There were very few data
on patients who had recently received HSCT (3% of all episodes).
A surprising univariable association found that patients with more
severe mucositis had a smaller chance of MDI than those with less
severe mucositis (Table 1). The estimated associations were
generally consistent betweyen studies (e.g., Figure 2). Notably,
there was no relationship demonstrated between age and risk
of MDI.
Per study proportion of missing predictors
Interleukin 8
Interleukin 6
Procalcitonin
C-reactive protein
Absolute monocyte count
Absolute neutrophil count
White cell count
Platelet count
Mucositis
Shock
Temperature at admission (C)
Out-patient status at onset
Presence of CVL
Malignancy type
Age
Sex
Ba
se
lS
PO
G
Be
rn
SP
O
G
Bo
nn
SP
O
G
H
ak
im
Ki
ta
no
vs
ki
Kl
aa
ss
en
Zu
ric
hS
PO
G
Haemoglobin
Antibiotics used
Clinical impression of severely unwell
Severe mucositis
Diastolic blood pressure
Systolic blood pressure
Pulse rate
Respiratory compromise
Respiratory rate
Type of CVL
Time since chemotherapy
Intensity of chemotherapy
Relapsed disease
Remission status
Marrow involvement
Al
ex
an
de
r
EO
RT
C-
XI
V
EO
RT
C-
IX
EO
RT
C-
XI
EO
RT
C-
XI
I
G
en
oa
Le
hr
nb
ec
he
r
PI
N
E
R
et
ro
Be
rn
Si
lva
Sp
as
so
va
St
yje
ws
ki
Su
ng
Te
zc
an
Ti
ss
in
g
Studies
Pr
ed
ict
or
s
100%
50%
25%
10%
5%
1%
Figure 1. Per study proportion of missing predictors. Grey items are predictors and studies that were included in the multivariable analyses.
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Table 1. Univariable associations with MDI
Predictor name N of episodes N of studies N of MDI OR 95% CI P-value
Patient demographics
Age (per 10-year increase) 5152 22 1412 1.0 0.98–1.1 0.38
Sex—female 1892 20 549 1 (Reference)
Sex—male 2400 656 0.96 0.84–1.1 0.56
Central venous line type—None 294 6 105 1 (Reference)
Central venous line type—Port 416 102 1.1 0.66–1.7 0.80
Central venous line type—Hickman 357 98 1.4 0.87–2.3 0.17
Central venous line type—Untunnelled 15 6 3.1 0.95–9.5 0.054
Type of malignancy—acute lymphoblastic leukaemia 1805 22 558 1 (Reference)
Type of malignancy—acute myeloid leukaemia 671 251 1.4 1.2–1.8 0.0002
Type of malignancy—relapsed acute leukaemia 192 71 1.4 1.0–2.0 0.06
Type of malignancy—osteosarcoma 204 26 0.38 0.25–0.59 o0.0001
Type of malignancy—Ewing’s sarcoma 173 26 0.54 0.32–0.78 0.002
Intensity of chemotherapy—Non-HSCT 2292 12 668 1 (Reference)
Intensity of chemotherapy—HSCT 193 52 1.5 0.96–2.46 0.08
Clinical features
Temperature (per degree Celsius) 2321 18 638 1.9 1.6–2.2 o0.0001
Physician assessment—‘not severely unwell’ 2348 17 603 1 (Reference)
Physician assessment—‘severely unwell’ 545 219 2.2 1.8–2.7 o0.0001
Clinical assessment—Not shocked 2243 12 699 1 (Reference)
Clinical assessment—Shock 135 73 2.4 1.7–3.4 o0.0001
Mucositis (per grades II–IV, compared with I) 442 11 133 0.89 0.80–1.0 0.050
In-patient at onset 838 18 272 1 (Reference)
Out-patient at onset 1973 482 0.69 0.53–0.91 0.0078
Investigations
Haemoglobin (g dl 1) 2658 16 765 1 0.99–1.1 0.11
Loge (white cell count, 10
6 l 1) 2845 16 679 0.72 0.66–0.78 o0.0001
Loge (platelets, 10
9 l 1) 2380 16 621 0.80 0.74–0.87 o0.0001
Loge (absolute monocyte count, cells per mm
3) 1469 11 431 0.80 0.75–0.86 o0.0001
Loge (absolute neutrophil count, cells per mm
3) 4382 21 1186 0.92 0.90–0.95 o0.0001
Loge (CRP, mgdl
 1) 1267 11 366 1.1 0.96–1.2 0.25
Loge (IL-8, pgml
 1) 477 5 94 1.8 1.5–2.3 o0.0001
Abbreviations: CI¼ confidence interval; HSCT¼ haemopoetic stem cell transplant; MDI¼microbiologically defined infection; OR¼odds ratio.
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Figure 2. Relation between probability of MDI and natural log of absolute monocyte count by study. Data points indicated by rug plot.
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The biomarkers with sufficient data to examine (o90%
missing) were C-reactive protein (CRP) and interleukin 8. Each
biomarker was assessed as the natural logarithm of its reported
value to reduce skewness. CRP was not significantly associated
with MDI (see Table 1) but IL-8 had a strongly significant
association with MDI (OR¼ 1.81, 95% CI 1.48–2.28, t2¼ 0.00,
I2¼ 0%) see Figure 3.
Multivariable model to predict microbiologically defined
infection. Because of the pattern of missing data, the final analysis
data set used to build the multivariable model contained 1101
episodes of FN from 742 patients in seven studies (Figure 1). Overall
24% (236) of those episodes exhibited a MDI. The analysis examined
15 candidate variables (Figure 1 and Supplementary Table 2, online),
giving an event-to-predictor ratio of 15.7. There was little between-
study heterogeneity in the parameter estimates, and no significant
difference in the univariable parameter estimates between-studies
included and excluded from the multivariable analysis.
Six simple variables were included in the model to predict MDI:
type of malignancy; maximum temperature; clinical evaluation of
being severely unwell; haemoglobin; white cell count; and absolute
monocyte count (AMC).
Logit(p(MDI)ijk)¼ aþ b0kþ b1j tumour typeijkþ b2
temperatureijkþ b3 unwellijkþ b4 Hbijkþ b5 loge (white cell count)ijk
þ b6 loge(absolute monocyte count)ijk,
where the subscript i refers to the ith episode, j the jth tumour
type, where b1j¼ 0 for acute lymphoblastic laekaemia, and k the
kth data set and b0kBN(0, t
2).
The predictions calibrated well against those expected even
when calculated using an average intercept (Figure 4, AUROC
0.723, 95% CI 0.711–0.759).
There appeared to be little optimism in the predictive estimates
as assessed by bootstrap; the mean difference in AUC values
between the bootstrapped estimates applied in their bootstrapped
data sets, and the estimates applied in the original data set, being
 0.0031 (0.7244 vs 0.7213). The heuristic shrinkage estimate for
the model (Steyerberg, 2009) was calculated to be 0.97, in keeping
with the very small differences produced by bootstrapping. Forcing
the antibiotic used into the model (sensitivity analysis) did not
affect its predictive performance. Using nonlinear forms did not
improve the model fit. Assessment of how the model performed
using all-bar-one cross-validation, also showed no significant
systematic differences in calibration (see Supplementary Figure 5).
Final parameter estimates can be found in Table 2.
Assessing if a complex model gives meaningful benefits over a
simpler one can be seen by comparing the AUROC values
apparent in the derivation data. The model using clinical variables
only (tumour type, temperature, severely unwell) gave an AUROC
of 0.697 (95% CI 0.660–0.734). The addition of the simple full
blood count variables (haemoglobin, white count and monocyte
count) improved the prediction further to an AUROC of 0.736
(95% CI 0.698–0.774).
DISCUSSION
The final multivariable predictive model had six simple compo-
nents: tumour type, temperature, clinical description of being
‘severely unwell’ and the results of measurements of haemoglobin
concentration, total white cell count and AMC. It showed
moderate discrimination (AUROC 0.723, 95% CI 0.711–0.759)
and good calibration between predicted and actual estimates of the
risk of MDI when assessed across the range of predictive values.
The model was robust to bootstrap and cross-validation sensitivity
analyses, and built by adding specialist investigations only after
considering the simpler pieces of information, ensuring that if
extra tests with additional costs are required, they are shown to add
predictive power to existing variables.(Altman et al, 1994).
The prediction model developed contained five items which
showed consistent relationships across the different study groups
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(type of malignancy, temperature, unwellness, AMC and total
white cell count) and one item (haemoglobin) that was less
consistent. The heterogeneity in this item makes it difficult to tell if
the inclusion of haemoglobin would be applicable in alternative
data sets and subsequently in clinical practice.
The inclusion of clinical impression of the child being
significantly unwell as a predictive variable is controversial. The
clinical impression of a trained physician is held by some to be of
great importance, and by others as unhelpfully subjective and
poorly reproducible. Previous investigators have demonstrated
objective replicability in paediatric oncology practice (Klaassen
et al, 2000), and shown its value in predicting infectious risk in
children without an oncological diagnosis(Bruel et al, 2012; Scott
et al, 2014) and it is a key element of the widely used (adult)
low-risk scoring system of the Multinational Supportive Care in
Cancer organisation. (Klastersky et al, 2000) We believe that our
analysis supports the use of this variable as providing additional
useful information above the objective elements of ‘vital signs’ and
full blood count in routine practice.
The value of using both total white count and AMC, rather than
one of these items or absolute neutrophil count (ANC), was
assessed during the model building. The use of AMC improved
AIC (model fit), discrimination and calibration compared with
ANC, as did the additional use of total white count. While this
appears to contradict the common understanding of how
neutrophil counts most importantly indicate the risk of
infection—the clinical situation is defined as ‘neutropenic sepsis’,
not ‘monocytopenic sepsis’—this analysis confirms data from
multiple prior investigations (Rackoff et al, 1996; Klaassen et al,
2000; Baorto et al, 2001; Tezcan et al, 2006). The finding may be
explained physiologically by both the neutrophil response to
infection and the observed pattern of marrow recovery after
chemotherapy, with monocytes preceding neutrophils (Mullen and
Buchanan, 1990).
The study was limited in its reliance on study-defined MDI as
the key outcome to be predicted, rather than a more comprehen-
sive, patient-important assessment of an adverse outcome of the
episode. The lack of a core, agreed definition of ‘significant adverse
outcome’ of FN remains a problem to researchers in this area
(Haeusler et al, 2013a, b). If one was to be universally agreed, the
PICNICC data may be suitable to recalibrate using an alternative
outcome.
Relying on the investigators’ original definition of MDI allows
the different quality control processes (e.g., numbers of sets of
blood cultures taken and volume of blood, or the use of
prophylactic antibiotics before presentation) to vary between-
studies. This may introduce different degrees of bias between-
studies, compared with the ‘true’ MDI status of patients. If this was
an important issue, the between-study heterogeneity in predictors
would have been marked, and this was not the case in this analysis.
The issue of missing data, almost entirely at the level of study
where predictor or outcome variables were ‘not recorded’ rather
than ‘missing’, led to a smaller data set being available for the
development of the multivariable analyses. Largely, this data set
was similar to the total data set when the univariable analyses were
compared, except for removing patients who had received HSCT.
Although developments in the handling of missing data within
studies using simulation have produced guidelines using imputa-
tion techniques to maximise the value of the IPD data collected
(Burgess et al, 2013; Resche-Rigon et al, 2013; Ahmed et al, 2014),
the application of such methods in the situation of unreported data
has yet to be explored. Future studies will benefit from adhering to
the core items recommended in the recent international position
paper on research in this area (Haeusler et al, 2013a, b).
The clinical implementation of the prediction model will require
it to be clearly understood by the clinical teams, based on sound
data, and easily integrated into practice. The full PICNICC model
has complexity (with the series of different predictors for type of
malignancy, and the use of log-transformed data) which makes it
likely to be unwieldy unless made easily applicable, for example on
a spreadsheet (for a basic version see: http://goo.gl/3AOa9R) or
smart phone ‘app’, into which the clinicians would enter the data
and return a calculated probability of MDI. The model, despite its
derivation from data taken from different geographies and eras,
requires evaluation in clinical practice from alternative data sets.
This could be accomplished by a further global collaboration,
building on the existing work, to formally assess the validity in
further new data sets, or by individual institutions against locally
collected data as a service improvement project. It also needs work
undertaking to determine how a prediction of risk can be turned
into a decision to employ a particular management strategy, which
will require qualitative work with health-care practitioners, families
and young people with febrile neutropenia.
Table 2. Final model beta-estimates and standard errors
Item
Beta
Estimate Std. Error
Odds
Ratio 95% CI
Acute myeloid
leukaemia
0.62 0.26 1.86 1.13–3.07
Brain  0.43 0.39 0.65 0.3–1.38
Carcinoma 15.84 1455.4 7500 0–10 000
Ewings  0.61 0.66 0.54 0.15–1.99
Germ cell tumour
(extracranial)
 0.07 0.88 0.94 0.17–5.21
Hepatoblastoma 0.45 0.57 1.57 0.51–4.8
High-grade brain
tumour
 0.33 0.46 0.72 0.29–1.78
Hodgkins  0.39 0.7 0.68 0.17–2.68
High-risk
neuroblastoma
0.88 0.66 2.4 0.66–8.76
LCH  13.39 1025.44 0 0–10 000
Low-grade brain
tumour
 13.45 677.94 0 0–10 000
Neuroblastoma 0.45 0.5 1.57 0.59–4.13
Non-Hodgkins
Lymphoma
 0.45 0.32 0.64 0.34–1.19
Osteosarcoma  1.13 0.57 0.32 0.11–0.98
Other tumour tyoe 0.76 0.77 2.13 0.47–9.6
Retinoblastoma 0.52 0.86 1.68 0.31–9
Relapsed acute
leukaemia
0.35 0.18 1.42 1–2.03
Rhabdomyosarcoma  0.23 0.32 0.79 0.42–1.48
Other sarcoma 0.18 0.82 1.2 0.24–5.98
Wilms  0.47 0.66 0.63 0.17–2.3
Centralised
temperature (actual
temperature—37 1C)
0.54 0.14 1.71 1.29–2.27
Physician impression
of clinically severe
unwell
0.75 0.19 2.11 1.45–3.08
Haemoglobin (g dl1) 0.17 0.05 1.19 1.08–1.31
Loge (white cell count
 106)
 0.28 0.1 0.75 0.62–0.92
Loge (absolute
monocyte count per
mm3)
 0.2 0.06 0.82 0.73–0.92
Abbreviations: CI¼ confidence interval; LCH¼ Langerhans cell histiocytosis. Note: acute
lymphoblastic leukaemia is the reference case. Classes in italics have too little information to
be clinically meaningful.
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We need to collect greater quantities of information on the
additional benefit of particular biomarkers and good quality data
on their comparative efficacy in initial risk stratification. Moving
beyond the initial treatment of FN, and focusing on how we should
treat patients with either a defined MDI or those without a clear
cause, the patterns of how biomarkers change over time which
reflect response to treatment will require evaluation, and also how
these patterns may vary both between individuals and within
individuals after different elements of their cancer treatment.
This individual patient data meta-analysis represents the largest
of its kind; the output of a global collaboration which has shared
thousands of items of data and developed a predictive model for
MDI which is robust to internal validation techniques. It has
demonstrated that such a project is feasible across many different
jurisdictions and eras of study, and can provide important
verifications and negations of commonly held beliefs.
This prediction model provides a robust method of determining
an individual’s chance of MDI during an episode of FN. It should
be validated, and used in the context of a clinical trial to enable
shared decisions to be made with parents or young people about
intensity and location of care for each episode. Such a study should
be achievable to prove or disprove the utility of this approach to
treatment (Manji et al, 2012) and solidly improve the management
of this frequent complication of childhood cancer therapy.
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